Results 101 to 110 of about 2,131 (185)

Tracking migraine outcomes over time by age and monoclonal antibody type: a retrospective, single-center, real-world study. [PDF]

Front Neurol
Mattioli I, Rondina A, Lanfranchi A, Ceccardi G, Di Pasquale M, Cresta E, Pilotto A, Rao R, Padovani A.   +8 more
europepmc   +1 more source

Evaluating the Complementary Nature of Randomized Controlled Trials and Real-World Evidence Using Over 5 Years of Experience with Fremanezumab: A Narrative Review. [PDF]

Adv Ther
Barbanti P, Smith T, Ramirez Campos V, Guevara Morel AE, Ling C, Bhogal P, Leonard C, Stark RJ.   +7 more
europepmc   +1 more source

Expanding preventive options for pediatric migraine: the use of anti-CGRP monoclonal antibodies for children and adolescents with migraine. [PDF]

Transl Pediatr
Krymchantowski AV.
europepmc   +1 more source

Three-year real-world effectiveness, treatment persistence, and planned discontinuation of anti-calcitonin gene-related peptide monoclonal antibodies for migraine prevention: a single-center cohort from Japan. [PDF]

Front Neurol
Kasai H, Yasumoto T, Kosuge S, Osanai A, Mizuma K, Futamura A, Kuroda T, Ono K, Murakami H.   +8 more
europepmc   +1 more source

Ultrasound assessment of cerebrovascular risk via breath-holding index in migraine patients treated with anti-CGRP monoclonal antibodies: a pilot study. [PDF]

J Ultrason
Barbella G, Antenucci P, Govoni V, Casetta I, Paciaroni M, Padroni M.   +5 more
europepmc   +1 more source

Cross-response to Calcitonin Gene-Related Peptide monoclonal antibodies in a real-world setting: analysis of prospective data collected in the French FHU InovPain registry. [PDF]

J Headache Pain
Ferrao-Malheiro S, Fabre R, Jiacomini T, Lanteri-Minet M.   +3 more
europepmc   +1 more source

Pharmacokinetics and Pharmacodynamics, Efficacy and Safety of Fremanezumab in Children and Adolescents with Migraine. [PDF]

Eur J Drug Metab Pharmacokinet
Iannone LF, Romozzi M, Papetti L, Toldo I, Valeriani M, Geppetti P.   +5 more
europepmc   +1 more source

Post-marketing safety of CGRP monoclonal antibodies and gepants: A systematic review of spontaneous reporting system data. [PDF]

Headache
Giacon M, Terrazzino S.
europepmc   +1 more source

Migraine, monoclonal antibodies, and monitoring: a review of pharmacovigilance in the era of biologics. [PDF]

Front Pharmacol
Guarnieri L, Bosco F, Corasaniti MT, Citraro R, De Sarro G.   +4 more
europepmc   +1 more source

Fremanezumab for the Preventive Treatment of Migraine

To evaluate the efficacy of monthly or quarterly fremanezumab in patients with chronic migraine or episodic migraine and documented inadequate response to 2, 3, or 4 classes of prior migraine preventive medications. This is an exploratory analysis of a randomized, double-blind, placebo-controlled, phase 3b trial for patients with chronic migraine or ...
Pazdera, Ladislav||, Cohen, Joshua M., Ning, Xiaoping, Campos, Verena Ramirez, Yang, Ronghua, Pozo-Rosich, Patricia||   +5 more
openaire   +1 more source